What to Ask Your Child’s Doctor Before Sports Injury Surgery

From the risks of opioid pain medications to alternative options, here’s how to advocate for a plan that helps your athlete ...

Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets

LG Chem is an established leader in pain management with a proven track record of delivering orthopedic pain solutions to ...
The Manila Times

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

Heron Therapeutics, Inc. (Nasdaq: HRTX) ('Heron” or the 'Company”), a commercial-stage biotechnology company, today announced ...
American Association of Individual Investors

Why Heron Therapeutics, Inc.’s (HRTX) Stock Is Up 18.11%

As of Friday, January 09, Heron Therapeutics, Inc.’s HRTX share price has surged by 18.11%, which has investors questioning ...

Pacira BioSciences: Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues

Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences ...

Heron Therapeutics, Inc.: Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF Largest Contributor to Q4 Growth

Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth ...
Benzinga.com

Injective (INJ) Price Prediction 2024 and 2025-2030

Analysts are forecasting that Injective (INJ) could reach $4.90 by 2030. Feeling confident about this Injective price prediction? You can trade Injective on Coinbase—and if you're new to the platform, ...
Drug Store News

Camber reflects on 2025 results

Camber expanded its team by 12%, filed 40 ANDAs and received 43 ANDA approvals in 2025. 2025 was a year filled with ...